Drugs / VHX-896
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | BYSANTI | — | 2026-02-20 | fda.gov ↗ |
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06494397 | Jul → Oct 2024 | bipolar I disorder, schizophrenia | Vanda Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT06803290 | Jun → Dec 2022 | — | Vanda Pharmaceuticals | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06830044 | Mar 2025 → Mar 2028 expected | major depressive disorder | Vanda Pharmaceuticals | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VHX-896 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06803290 ↗ |
| Known as | Milsaperidone | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06830044 ↗ |
| Route | Oral | “oral tablet” NCT06494397 ↗ |